Treatment of Acute Immune-mediated Neuropathies: Guillain-Barré Syndrome and Clinical Variants

ABSTRACT

The author reviews current treatment approaches for the management of acute immune-mediated peripheral neuropathies, including the Guillain-Barré syndrome together with the clinical variants, which are acute inflammatory demyelinating polyradiculoneuropathy, acute motor axonal neuropathy, acute motor and sensory axonal neuropathy, and the Fisher syndrome. A summary of clinical evidence for drug therapies is provided, with additional recommendations for commonly used treatment modalities including a focus on the approach to using intravenous immune globulin and plasma exchange therapy.

KEYWORDS

Guillain-Barré syndrome - acute inflammatory demyelinating polyradiculoneuropathy - acute motor axonal neuropathy - acute motor and sensory axonal neuropathy - Fisher syndrome - intravenous immune globulin - plasma exchange

REFERENCES

• 1 Hughes R A, Wijdicks E F, Barohn R Quality Standards Subcommittee of the American Academy of Neurology et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2003;  61(6) 736-740
• 2 Raphaël J C, Chevret S, Hughes R A, Annane D. Plasma exchange for Guillain-Barré syndrome.  Cochrane Database Syst Rev. 2002;  (2) CD001798
• 3 Lehmann H C, Hartung H P, Meyer Zu Hörste G, Kieseier B C. Plasma exchange in immune-mediated neuropathies.  Curr Opin Neurol. 2008;  21(5) 547-554
• 4 Mehndiratta M M, Hughes R A, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.  Cochrane Database Syst Rev. 2004;  (3) CD003906
• 5 Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures.  J Clin Apher. 2007;  22(5) 270-276
• 6 Hughes R A, Raphaël J C, Swan A V, van Doorn P A. Intravenous immunoglobulin for Guillain-Barré syndrome.  Cochrane Database Syst Rev. 2006;  (1) CD002063
• 7 Kuitwaard K, de Gelder J, Tio-Gillen A P et al.. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.  Ann Neurol. 2009;  66(5) 597-603
• 8 Gelfand E W. Differences between IGIV products: impact on clinical outcome.  Int Immunopharmacol. 2006;  6(4) 592-599
• 9 Siegel J. Safety considerations in IGIV utilization.  Int Immunopharmacol. 2006;  6(4) 523-527
• 10 The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome . Appropriate number of plasma exchanges in Guillain-Barré syndrome.  Ann Neurol. 1997;  41(3) 298-306
• 11 French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome . Plasma exchange in Guillain-Barré syndrome: one-year follow-up.  Ann Neurol. 1992;  32(1) 94-97
• 12 The Guillain-Barre Syndrome Study Group . Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group.  Neurology. 1985;  35(8) 1096-1104
• 13 Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome.  Ann Neurol. 1987;  22(6) 753-761
• 14 Kleyweg R P, van der Meché F G. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.  J Neurol Neurosurg Psychiatry. 1991;  54(11) 957-960
• 15 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group . Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome.  Lancet. 1997;  349(9047) 225-230
• 16 Elovaara I, Apostolski S, van Doorn P EFNS et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.  Eur J Neurol. 2008;  15(9) 893-908
• 17 Farcas P, Avnun L, Frisher S, Herishanu Y O, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome.  Lancet. 1997;  350(9093) 1747
• 18 Hughes R A, Swan A V, van Koningsveld R, van Doorn P A. Corticosteroids for Guillain-Barré syndrome.  Cochrane Database Syst Rev. 2006;  (2) CD001446
• 19 van Koningsveld R, Schmitz P I, Meché F G, Visser L H, Meulstee J, van Doorn P A. Dutch GBS study group . Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.  Lancet. 2004;  363(9404) 192-196
• 20 Pritchard J, Gray I A, Idrissova Z R et al.. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.  Neurology. 2003;  61(9) 1282-1284
• 21 Garssen M P, van Koningsveld R, van Doorn P A et al.. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study.  J Neurol Neurosurg Psychiatry. 2007;  78(9) 1012-1013
• 22 Hughes R A, Wijdicks E F, Benson E Multidisciplinary Consensus Group et al. Supportive care for patients with Guillain-Barré syndrome.  Arch Neurol. 2005;  62(8) 1194-1198
• 23 Moulin D E, Hagen N, Feasby T E, Amireh R, Hahn A. Pain in Guillain-Barré syndrome.  Neurology. 1997;  48(2) 328-331
• 24 Pandey C K, Bose N, Garg G et al.. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study.  Anesth Analg. 2002;  95(6) 1719-1723
• 25 Rosenfeld B, Borel C, Hanley D. Epidural morphine treatment of pain in Guillain-Barré syndrome.  Arch Neurol. 1986;  43(11) 1194-1196
• 26 Kuwabara S, Mori M, Ogawara K et al.. Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody.  Muscle Nerve. 2001;  24(1) 54-58
• 27 Visser L H, Van der Meché F G, Van Doorn P A Dutch Guillain-Barré Study Group et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features.  Brain. 1995;  118(Pt 4) 841-847
• 28 Jacobs B C, van Doorn P A, Schmitz P I et al.. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.  Ann Neurol. 1996;  40(2) 181-187
• 29 Dada M A, Kaplan A A. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.  Ther Apher Dial. 2004;  8(5) 409-412
• 30 Hiraga A, Mori M, Ogawara K et al.. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome.  J Neurol Neurosurg Psychiatry. 2005;  76(5) 719-722
• 31 Griffin J W, Li C Y, Ho T W et al.. Pathology of the motor-sensory axonal Guillain-Barré syndrome.  Ann Neurol. 1996;  39(1) 17-28
• 32 Rostásy K M, Huppke P, Beckers B et al.. Acute motor and sensory axonal neuropathy (AMSAN) in a 15-year-old boy presenting with severe pain and distal muscle weakness.  Neuropediatrics. 2005;  36(4) 260-264
• 33 Chowdhury D, Arora A. Axonal Guillain-Barré syndrome: a critical review.  Acta Neurol Scand. 2001;  103(5) 267-277
• 34 Overell J R, Hsieh S T, Odaka M, Yuki N, Willison H J. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders.  Cochrane Database Syst Rev. 2007;  (1) CD004761
• 35 Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller-Fisher syndrome.  Neurology. 2007;  68(14) 1144-1146
• 36 Kurmann P T, Van Linthoudt D, So A K. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab.  Clin Rheumatol. 2009;  28(1) 93-94
• 37 Bernsen R A, Jager A E, Schmitz P I, van der Meché F G. Long-term sensory deficit after Guillain-Barré syndrome.  J Neurol. 2001;  248(6) 483-486